- Roche Holding Ag
- 16 May 2024 11:22:19
Source: Sharecast
Announcing the results from phase Ib trials of CT-388, the Basel-based firm said that over 24 weeks, the once-weekly injection had achieved "clinically meaningful and statistically significant" weight loss in healthy test subjects.
The mean placebo-adjusted weight loss achieved was 18.8%.
Levi Garraway, chief medical officer and head of global product development at Roche, said: "The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes, and underscore its potential to become a best-in-class therapy with durable weight loss and glucose control."
As at 1115 BST, shares in Roche were trading 3% higher.
The weight loss sector is currently dominated by Novo Nordisk, with its drugs Wegovy and Ozempic, and Eli Lilly & Co’s Zepbound.
Along with CT-388, the treatments belong to a new class of drug called GLP-1 agonists. Developed for type 2 diabetes, they reduce food cravings and cause the stomach to empty more slowly.
Analysts expect GLP-1 drugs to surpass cancer immunotherapies as the best-selling medicines as early as this year, according to Reuters.